
Fresh money for Carbios
In order to retain shareholders' preemptive subscription rights, French plastics recycling specialist Carbios SAS has announced the beginning of a...

Lilly presents impressing results for Alzheimer's drug donanemab
Donanemab is the second antibody, after Eisai’s/Biogen’s accelarated approved lecanemab, that can slow the progression of dementia in early-stage...

Pairwise and Bayer collaborate to CRISPR short-stem maize
Following Leaps by Bayer's co-investment in a US$90m Series B financing in Pairwise Plants Services Inc. in 2021,German seed giant Bayer AG has...

Retinopathy: Golgi and Breye join forces
The two companies announced their collaboration, which aims to find treatment options for both early-stage diabetic retinopathy (DR) and dry-AMD...

Mystery solved: Mysthera Theapeutics launches with $3.5m
Mysthera Therapeutics AG was just founded in Basel, Switzerland by Forty51 Ventures with $3.5m seed capital. Pursuing a first-in-class...

Mithra raises €20m through private placement
Under the terms of the Private Placement, Armistice Capital committed to subscribe for 10 million new shares atz a share price of 2€ per share , of...

Nanobiotix SA licences NBTXR3 to J&J
NBTXR3 is currently being evaluated across different solid tumour indications including NANORAY‑312, a global Phase III pivotal study in ...